Established Osteoarthritis (Kellgren-Lawrence > 3)
Minimum joint space > 2 mm as measured on AP radiograph
Hip dysplasia (center edge angle < 20° on AP radiograph)
Patients with clinically significant cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes
Patients with ongoing infection including HIV and Hepatitis
Patient with history of osteomyelitis/septic arthritis
Anticoagulation therapy
Patients who are pregnant or breast feeding
Patients with systemic, rheumatic or inflammatory disease of the knee or chondrocalcinosis, hemochromatosis, inflammatory arthritis, arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia, hemophilic arthropathy, infectious arthritis, Charcot's knee joint, villonodular synovitis, and synovial chondromatosis
Patients taking immunosuppressant medication
Patients with abnormal hematology or serum chemistry lab results
Patients receiving injection to treatment knee within 2 months of study enrollment
BMI greater than 35 or less than 20

NCT02920177_exc_T1
Condition
Osteoarthritis
NCT02920177_exc_T2
Measurement
Kellgren-Lawrence
NCT02920177_exc_T3
Value
> 3
NCT02920177_exc_T4
Measurement
Minimum joint space
NCT02920177_exc_T5
Value
> 2 mm
NCT02920177_exc_T6
Procedure
AP radiograph
NCT02920177_exc_T7
Condition
Hip dysplasia
NCT02920177_exc_T8
Measurement
center edge angle
NCT02920177_exc_T9
Value
< 20°
NCT02920177_exc_T10
Procedure
AP radiograph
NCT02920177_exc_T11
Condition
diovascular, r ease, c
NCT02920177_exc_T12
Condition
al, h ease, c
NCT02920177_exc_T13
Condition
atic, e ease, c
NCT02920177_exc_T14
Condition
endocrine disease
NCT02920177_exc_T15
Condition
cancer
NCT02920177_exc_T16
Condition
diabetes
NCT02920177_exc_T17
Qualifier
significant
NCT02920177_exc_T18
Scope
cardiovascular, renal, hepatic, endocrine disease, cancer or diabetes
NCT02920177_exc_T19
Condition
infection
NCT02920177_exc_T20
Qualifier
ongoing
NCT02920177_exc_T21
Condition
HIV
NCT02920177_exc_T22
Condition
Hepatitis
NCT02920177_exc_T24
Scope
HIV and Hepatitis
NCT02920177_exc_T25
Condition
septic arthritis
NCT02920177_exc_T26
Condition
osteomyelitis
NCT02920177_exc_T28
Procedure
Anticoagulation therapy
NCT02920177_exc_T30
Condition
chondrocalcinosis
NCT02920177_exc_T31
Condition
hemochromatosis
NCT02920177_exc_T32
Condition
inflammatory arthritis
NCT02920177_exc_T33
Condition
arthropathy of the knee
NCT02920177_exc_T34
Condition
Paget's disease
NCT02920177_exc_T35
Condition
hemophilic arthropathy
NCT02920177_exc_T36
Condition
infectious arthritis
NCT02920177_exc_T37
Condition
Charcot's knee joint
NCT02920177_exc_T38
Condition
villonodular synovitis
NCT02920177_exc_T39
Condition
synovial chondromatosis
NCT02920177_exc_T41
Qualifier
femur
NCT02920177_exc_T42
Qualifier
tibia
NCT02920177_exc_T43
Qualifier
juxta-articular
NCT02920177_exc_T44
Qualifier
knee
NCT02920177_exc_T45
Condition
inflammatory disease
NCT02920177_exc_T46
Condition
c or infl of the
NCT02920177_exc_T47
Condition
, rheuma of the
NCT02920177_exc_T48
Scope
systemic, rheumatic or inflammatory disease
NCT02920177_exc_T49
Scope
femur or tibia
NCT02920177_exc_T50
Scope
arthropathy of the knee associated with juxta-articular Paget's disease of the femur or tibia
NCT02920177_exc_T51
Procedure
immunosuppressant medication
NCT02920177_exc_T52
Measurement
serum chemistry lab
NCT02920177_exc_T53
Measurement
 or seru s
P
NCT02920177_exc_T54
Value
abnormal
NCT02920177_exc_T55
Scope
hematology or serum chemistry lab
NCT02920177_exc_T56
Procedure
injection
NCT02920177_exc_T57
Qualifier
knee
NCT02920177_exc_T58
Temporal
within 2 months of study enrollment
NCT02920177_exc_T59
Reference_point
study enrollment
NCT02920177_exc_T60
Measurement
BMI
NCT02920177_exc_T61
Value
greater than 35
NCT02920177_exc_T62
Value
less than 20
NCT02920177_exc_T63
Scope
greater than 35 or less than 20